|2.91||-0.3000||-9.35%||Vol 174.11K||1Y Perf -80.26%|
|Jun 28th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||15.71||Analyst Rating||Moderate Buy 2.14|
|Potential %||439.86||Finscreener Ranking||★★★ 48.80|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★ 45.51|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★+ 48.96|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||4.31||Earnings Rating||Strong Buy|
|Market Cap||132.38M||Earnings Date||4th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Aug 2022|
|Estimated EPS Next Report||-0.55|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||180.46K|
|Avg. Monthly Volume||151.72K|
|Avg. Quarterly Volume||147.92K|
Cellectis S.A. (NASDAQ: CLLS) stock closed at 3.21 per share at the end of the most recent trading day (a 2.88% change compared to the prior day closing price) with a volume of 72.80K shares and market capitalization of 132.38M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 264 people. Cellectis S.A. CEO is Andre Choulika.
The one-year performance of Cellectis S.A. stock is -80.26%, while year-to-date (YTD) performance is -60.47%. CLLS stock has a five-year performance of -87.34%. Its 52-week range is between 2.3 and 16.45, which gives CLLS stock a 52-week price range ratio of 4.31%
Cellectis S.A. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 0.70, a price-to-sale (PS) ratio of 4.38, a price to cashflow ratio of 265.50, a PEG ratio of 2.32, a ROA of -35.08%, a ROC of -38.32% and a ROE of -61.24%. The company’s profit margin is -86.60%, its EBITDA margin is -357.70%, and its revenue ttm is $33.39 Million , which makes it $0.73 revenue per share.
Of the last four earnings reports from Cellectis S.A., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. Cellectis S.A.’s next earnings report date is 04th Aug 2022.
The consensus rating of Wall Street analysts for Cellectis S.A. is Moderate Buy (2.14), with a target price of $15.71, which is +439.86% compared to the current price. The earnings rating for Cellectis S.A. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cellectis S.A. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cellectis S.A. has a Neutral technical analysis rating based on Technical Indicators (ADX : 24.20, ATR14 : 0.27, CCI20 : 34.18, Chaikin Money Flow : 0.02, MACD : -0.13, Money Flow Index : 57.02, ROC : 1.90, RSI : 52.04, STOCH (14,3) : 94.79, STOCH RSI : 1.00, UO : 63.16, Williams %R : -5.21), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cellectis S.A. in the last 12-months were:
Sun, 15 May 2022 14:19 GMT Cellectis SA (CLLS) Gets a Hold Rating from William Blair- TipRanks. All rights reserved.
Mon, 11 Apr 2022 16:25 GMT Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and Nuvectis Pharma (NVCT)- TipRanks. All rights reserved.
Tue, 08 Mar 2022 06:37 GMT Cellectis SA (CLLS) Receives a Buy from JMP Securities- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.